Press coverage about Lumenis (NASDAQ:LMNS) has been trending positive on Friday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Lumenis earned a daily sentiment score of 0.50 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.9723814520318 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
TRADEMARK VIOLATION WARNING: “Lumenis (LMNS) Earns Media Impact Rating of 0.50” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3355092/lumenis-lmns-earns-media-impact-rating-of-0-50.html.
Lumenis Company Profile
Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies.
Receive News & Ratings for Lumenis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumenis and related companies with MarketBeat.com's FREE daily email newsletter.